NGM · Ngm Biopharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue | $4.42M | $55.33M | $77.88M | $87.37M | $108.67M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $118.04M | $181.07M | $161.71M | $163.97M | $79.74M |
| SG&A | $37.84M | $40.52M | $36.87M | $27.23M | $14.83M |
| Total Operating Expenses | $155.88M | $221.58M | $198.58M | $191.20M | $94.57M |
| D&A | $2.22M | $4.04M | $6.09M | $6.55M | $7.22M |
| Operating Income | ($151.46M) | ($166.25M) | ($120.69M) | ($103.83M) | ($17.43M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | - | - | - | - | ($1.06M) |
| Net Income | ($142.38M) | ($162.67M) | ($120.33M) | ($102.49M) | ($14.16M) |
| EPS - Basic | ($1.73) | ($2.03) | ($1.50) | - | - |
| EPS - Diluted | ($1.73) | ($2.03) | ($1.50) | - | - |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | $55.82M | $73.46M | $151.79M | $147.02M | $25.59M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $2.98M | $8.45M | $5.25M | $9.66M | $9.03M |
| Current Assets | $156.44M | $288.86M | $379.28M | $308.43M | $355.25M |
| Total Assets | $168.87M | $307.40M | $402.39M | $329.04M | $380.40M |
| Current Liabilities | $20.08M | $47.84M | $61.35M | $42.58M | $39.72M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $20.23M | $47.84M | $66.74M | $49.00M | $49.68M |
| Stockholders' Equity | $148.64M | $259.56M | $335.65M | $280.04M | ($115.06M) |
| Retained Earnings | ($724.01M) | ($581.63M) | ($418.97M) | ($298.63M) | ($196.14M) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($132.20M) | ($144.44M) | ($73.23M) | ($83.50M) | ($17.41M) |
| Investing Cash Flow | $114.29M | $14.32M | ($71.65M) | ($51.00M) | ($2.80M) |
| Financing Cash Flow | $1.77M | $54.23M | $149.66M | $35.54M | $339.0K |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -3429.1% | -300.5% | -155.0% | -118.8% | -16.0% |
| EBITDA margin | -3378.8% | -293.2% | -147.2% | -111.3% | -9.4% |
| Net margin | -3223.3% | -294.0% | -154.5% | -117.3% | -13.0% |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - |
| R&D / Revenue | 2672.4% | 327.2% | 207.6% | 187.7% | 73.4% |
| SG&A / Revenue | 856.7% | 73.2% | 47.3% | 31.2% | 13.6% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -84.3% | -52.9% | -29.9% | -31.1% | -3.7% |
| Return on equity | -95.8% | -62.7% | -35.9% | -36.6% | 12.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 7.79 | 6.04 | 6.18 | 7.24 | 8.94 |
| Quick ratio | 7.79 | 6.04 | 6.18 | 7.24 | 8.94 |
| Cash ratio | 2.78 | 1.54 | 2.47 | 3.45 | 0.64 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.18 | 1.20 | 1.17 | -3.31 |
| Liabilities / Assets | 0.12 | 0.16 | 0.17 | 0.15 | 0.13 |
| Efficiency | |||||
| Asset turnover | 0.03 | 0.18 | 0.19 | 0.27 | 0.29 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -92.0% | -29.0% | -10.9% | -19.6% | - |
| Revenue CAGR (3y) | -63.0% | -20.1% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 8.9% | -37.7% | -16.2% | -495.9% | - |
| Net income growth (YoY) | 12.5% | -35.2% | -17.4% | -623.8% | - |
| EPS growth (YoY) | 14.8% | -35.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -42.7% | -22.7% | 19.9% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$4.90M totalLicense$4.90M · 100.0%
Stability scores
Altman Z′
FY 2023 · bankruptcy risk
-2.73
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2023 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NGM BIOPHARMACEUTICALS INC against the 5 most active filers in the same SIC group.